Published in Am J Med on April 01, 1991
Human immunodeficiency virus infection and pneumothorax. J Thorac Dis (2014) 0.94
The era of aerosol pentamidine prophylaxis: the beginning or the end? Am J Med (1991) 0.75
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49
Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med (1991) 7.01
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1984) 4.64
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med (1995) 2.72
Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A (2001) 2.61
Blastomycosis. Am Rev Respir Dis (1979) 2.50
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae. J Antimicrob Chemother (1983) 2.25
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 2.20
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med (1996) 2.10
Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care (2003) 2.04
Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet (1996) 2.03
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88
Permeability properties of the intact mammalian bladder epithelium. Am J Physiol (1996) 1.84
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology (1993) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Chemical and microphysical characterization of ambient aerosols with the aerodyne aerosol mass spectrometer. Mass Spectrom Rev (2007) 1.80
Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.79
Use of ciprofloxacin for successful eradication of bacteremia due to Campylobacter cinaedi in a human immunodeficiency virus-infected person. Rev Infect Dis (1992) 1.75
Epidemic giardiasis caused by a contaminated public water supply. Am J Public Health (1988) 1.72
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Nosocomial outbreak of respiratory tract colonization with Mycobacterium fortuitum: demonstration of the usefulness of pulsed-field gel electrophoresis in an epidemiologic investigation. Am Rev Respir Dis (1991) 1.64
Alveolar hemorrhage syndromes: diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine (Baltimore) (1984) 1.62
Some aspects of immunity in patients with cystic fibrosis. Clin Exp Immunol (1974) 1.60
2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology (1994) 1.59
Weight loss methods used by African American and Euro-American women. Res Nurs Health (1997) 1.59
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci U S A (1993) 1.54
Asymptomatic blood donor with a false positive HTLV-III Western blot. N Engl J Med (1986) 1.54
HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses (1996) 1.51
Dispersal as a regional process affecting the local dynamics of marine and stream benthic invertebrates. Trends Ecol Evol (1996) 1.50
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS (1993) 1.48
Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J Infect Dis (1982) 1.47
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med (1993) 1.47
Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol (2000) 1.47
Adrenal insufficiency in the antiphospholipid antibody syndrome. Semin Arthritis Rheum (1995) 1.46
Nutritional supplementation in treatment of cystic fibrosis of the pancreas. Am J Dis Child (1973) 1.44
Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A (1996) 1.44
Pneumonia due to Bordetella bronchiseptica in a patient with AIDS. Rev Infect Dis (1992) 1.42
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses (1995) 1.42
Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav (2013) 1.41
The normal immune response and what can go wrong. A classification of immunologic disorders. Med Clin North Am (1985) 1.41
Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum (1984) 1.41
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis (1994) 1.40
Predictors of optimal virological response to potent antiretroviral therapy. AIDS (1999) 1.40
Giardia transmission in a swimming pool. Am J Public Health (1988) 1.39
Immune complexes in cystic fibrosis. Br Med J (1975) 1.36
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther (1995) 1.34
Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis (1999) 1.32
Nontuberculous mycobacterial infections. Med Clin North Am (1997) 1.28
Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol (2001) 1.28
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses (2006) 1.26
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med (2000) 1.20
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
Disseminated histoplasmosis in immunologically suppressed patients. Occurrence in a nonendemic area. Am J Med (1978) 1.20
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol (2001) 1.18
Prevalence of antibody to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion (1992) 1.16
Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol (2014) 1.14
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother (2000) 1.12
Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis (1991) 1.11
Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis (2001) 1.11
Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. Int J Tuberc Lung Dis (2011) 1.11
Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. Clin Infect Dis (1994) 1.09
The species of coccidia occurring in cattle and sheep in the South-West of England. Parasitology (1966) 1.09
Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res (2000) 1.09
Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med (1996) 1.07
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol (2008) 1.07
Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care (2002) 1.06
Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs. Antimicrob Agents Chemother (1985) 1.05
Immediate hypersensitivity in patients with cystic fibrosis. Clin Allergy (1975) 1.05
Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9). AIDS Care (2010) 1.04
Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut (2008) 1.03
Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS (1997) 1.03
Q fever endocarditis. Am J Med Sci (1986) 1.02
Immunology of a serum sickness/vasculitis reaction secondary to streptokinase used for acute myocardial infarction. Clin Exp Rheumatol (1989) 1.02
An uncommon Helicobacter isolate from blood: evidence of a group of Helicobacter spp. pathogenic in AIDS patients. J Clin Microbiol (1999) 1.01
The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Qual Life Res (1997) 1.01
Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med (1996) 1.01
Detection of tumorigenesis in rat bladders with optical coherence tomography. Med Phys (2001) 1.00